Tags : Stake

Gilead to Acquire Tizona’s Stakes for $300M

Shots: Gilead invests $300M to obtain 49.9% equity interest in Tizona and receives an exclusive option to acquire remaining stakes of Tizona for up to an additional $1.25B that includes an option exercise fee and milestones. The transaction is expected to be closed in Q3’20 Gilead can exercise its option following the results of a […]Read More

GSK to Acquire 10% stake in CureVac for $163M

Shots: GSK will invest $163M (€150m) in CureVac for a 10% stake to collaborate for the research, development, manufacturing, and commercialization of up to five mRNA-based vaccines and mAbs targeting infectious disease pathogens excluding CureVac’s existing COVID-19 mRNA and rabies vaccines research programs CureVac to receive $137M (€120m) as upfront, $34.3 (€30m) as one-time reimbursable […]Read More

Cipla to Acquire 21.85% Stake in GoApptiv for ~$1.2M

Shots: Cipla to acquire 21.85% stake in GoApptiv on a fully diluted basis for ~1.2M (₹9 crores) which included ₹5.80 crores in the first stage and ₹3.20 crores in the second stage. The acquisition will expand the reach of Cipla’s brand in tier three-plus towns In the first stage, a subscription of 15,392 compulsorily convertible […]Read More

Lupin to Divest its Stake in Kyowa to Unison for

Shots: Lupin’s subsidiary Nanomi to sell its entire stake (99.82%) in Kyowa to Unison’s entity Plutus in an all-cash transaction for an enterprise value of ~$525.87M and will generate post-tax net cash inflow of ~$300M.  The transfer is expected to be completed in Mar’2020 The divestiture will strengthen Lupin’s balance sheet and its growth capital […]Read More

Yas Holding to Acquire Stake in Alvotech and Signs an

Shots: Alvotech to receive ~$45M as up front, equity investment, milestone while Yas Holding has acquired a 2.5% stake in Alvotech business and get rights to commercialize Alvotech’s three biosimilar candidates in MENA region The investment will complement Yas holding an existing portfolio and expands its footprints in health & pharmaceutical sector both in the […]Read More

Gilead to Raise Stake in Galapagos with ~$5.1B Deal

Shots: Galapagos to receive $3.95B upfront and $1.1B equity investment. Gilead to get rights of Galapagos’ GLPG1690 for IPF, option rights of GLPG1972 for OA in the US and option rights of all Galapagos’ current and future clinical programs (Ex-EU) Gilead has an option for GLPG1972 and will pay $250M license fee, $200M post to […]Read More